Expertise in
54
conditions

Dr. Chafic Y. Karam

Neurology
3400 Civic Center Boulevard, South Pavilion, 2nd Floor, 
Philadelphia, PA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
54
conditions
3400 Civic Center Boulevard, South Pavilion, 2nd Floor, 
Philadelphia, PA 

Overview

Chafic Karam is a Neurologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Karam is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Transthyretin Amyloidosis, Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Tissue Biopsy, and Laminectomy.

Dr. Karam is board certified in Neuromuscular Medicine, 2012 and Neurology, 2011. He is actively involved in clinical research, co-authoring 111 peer reviewed articles and participating in 8 clinical trials. Dr. Karam is currently accepting new patients.

Specialties

Neurology

Licenses

Psychiatry & Neurology in OR

Board Certifications

Neuromuscular Medicine, 2012
Neurology, 2011

Hospital Affiliations

Hospital Of Univ Of Pennsylvania
Pennsylvania Hospital
Penn Presbyterian Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
PacificSource
  • PPO
Provider Partners Health Plan
  • MEDICARE SNP
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 23 Less Insurance Carriers -

Locations

Penn Neuroscience Center - Neurology
3400 Civic Center Boulevard, South Pavilion, 2nd Floor, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Karam has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Multifocal Motor Neuropathy
Porphyria
Peripheral Neuropathy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
Genomic Translation for Amyotrophic Lateral Sclerosis Care
Genomic Translation for Amyotrophic Lateral Sclerosis Care
Enrollment Status: Completed
Publish Date: August 19, 2022
Fluid Biomarkers With Deep Phenotyping in Patients With ALS
Fluid Biomarkers With Deep Phenotyping in Patients With ALS
Enrollment Status: Completed
Publish Date: December 16, 2021
A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
Enrollment Status: Terminated
Publish Date: August 20, 2020
Intervention Type: Drug
Study Phase: Phase 1
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: October 17, 2018
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)
Enrollment Status: Completed
Publish Date: July 06, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials

111 Total Publications

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Journal: Neurology
Published: June 16, 2026
Similar Doctors
Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required
Before you request

Penn Neuroscience Center - Neurology

3400 Civic Center Boulevard, South Pavilion, 2nd Floor, 
Philadelphia, PA 
 (0.1 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Lynch is a Neurologist practicing medicine in Philadelphia, Pennsylvania. Dr. Lynch is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Friedreich Ataxia, Spinocerebellar Ataxia, Drug Induced Dyskinesia, Hereditary Ataxia, and Spinal Fusion. Dr. Lynch is board certified in Neurology, 1993. Dr. Lynch is currently accepting new patients.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required
Before you request

Vickie & Jack Farber Institute For Neuroscience - Honickman Center

1101 Chestnut Street, Floor 10, 
Philadelphia, PA 
 (1.8 miles away)
215-955-1222
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Sperling is a Neurologist practicing medicine in Philadelphia, Pennsylvania. Dr. Sperling is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Seizures, Epilepsy, Generalized Tonic-Clonic Seizure, Absence Seizure, and Deep Brain Stimulation. Dr. Sperling is board certified in Neurology. Dr. Sperling is currently accepting new patients.

Expertise in
48
conditions
Expertise in
48
conditions
Referral may be required
Before you request

Penn Nerve Center University City

3737 Market Street, 7th Floor, 
Philadelphia, PA 
 (0.7 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lauren Elman is a Neurologist practicing medicine in Philadelphia, Pennsylvania. Dr. Elman is highly rated in 48 conditions, according to our data. Her clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Myotonic Dystrophy, and Myotonic Dystrophy Type 2. Dr. Elman is board certified in Neurology, 2003. Dr. Elman is currently accepting new patients.

Frequently Asked Questions about Dr. Chafic Y. Karam

How do I make an appointment with Dr. Chafic Y. Karam?

You can book an appointment with Dr. Chafic Y. Karam by calling their office at 800-789-7366. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Chafic Y. Karam a top-rated expert for Transthyretin Amyloidosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Chafic Y. Karam is classified as an Elite expert for Transthyretin Amyloidosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Chafic Y. Karam specialize in?

While Dr. Chafic Y. Karam is a Neurology, they have specific expertise in Transthyretin Amyloidosis, Chronic Inflammatory Demyelinating Polyneuropathy, and Myasthenia Gravis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Chafic Y. Karam participate in research or clinical trials?

Yes. Dr. Chafic Y. Karam has published 111 articles and abstracts on conditions like Transthyretin Amyloidosis. You can view a list of Dr. Chafic Y. Karam's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Chafic Y. Karam accept my insurance?

Dr. Chafic Y. Karam accepts most major insurance plans, including Aetna and Avalon Health Care. We recommend calling the office directly at 800-789-7366 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Karam's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 39 Advanced Conditions
View All 66 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile